Related Experiment Video

Updated: May 28, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer

Jonathan W Riess1, Joel W Neal

  • 1Stanford University/Stanford Cancer Center, Stanford, California, USA.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|October 19, 2011
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Experiment Videos

Last Updated: May 28, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Articles linked to this work by shared authors, journal, and citation graph.

SUNRAY-02: a study of olomorasib combined with immunotherapy in stage II-III KRAS G12C-mutant non-small cell lung cancer after definitive therapy.

Future oncology (London, England)·2026

Metabolomic and lipidomic profiling reveals distinct subtypes of glioblastoma IDH-wildtype and shared metabolic features with astrocytoma IDH-mutant grade 4.

Neuro-oncology advances·2026

A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer.

Oncoimmunology·2026

Efficacy of Bioengineered PD-L1 siRNA for Immunotherapy Against Non-Small Cell Lung Cancer Cells.

Non-coding RNA·2026

Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial.

The Lancet. Respiratory medicine·2026

Tobacco Use and Cessation Patterns Among Cancer Survivors: Results From Nine ECOG-ACRIN Cancer Research Group Trials.

JCO oncology practice·2026

Advances in Pathology: Journal of Thoracic Oncology 20th Anniversary Series.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Brief Report: Validation of the Sybil Lung Cancer Risk Prediction Model in a Predominantly Black Screening Cohort.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Efficacy and safety of HER2 directed therapies for advanced HER2-mutant non-small-cell lung cancer - a systematic review and meta-analysis.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Gene-Specific Analysis of Clonal Hematopoiesis Identifies the Association between ASXL1 and Lung Cancer Risk.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Grade 3 Lung Carcinoids/NETs: The IASLC Pathology Committee Study with Proposal of a New Diagnostic Category.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Long-Term Benefit With First-Line Osimertinib Monotherapy in EGFR-Mutated Advanced NSCLC in the Era of Intensified First-Line Therapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us